An oral drug that blocks activity of enzymes that change proteins in cells that leads to cancer is being tested at the National Institutes of Health.
R935788 or Fostamatinib, a protein kinase inhibitor, is in a Phase II clinical trial for patients with several types of advanced cancer, including colorectal cancer. Patients whose cancer has gotten worse on previous treatment are eligible to participate. The trial is being conducted at the NIH Clinical Center in Bethesda, Maryland. Read the rest of this entry »